Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Enzalutamide patent expiry?

See the DrugPatentWatch profile for Enzalutamide

Enzalutamide (brand name Xtandi) is an androgen‑receptor antagonist approved for metastatic castration‑resistant prostate cancer (mCRPC).
Its original patents were filed by Janssen Pharmaceuticals (a division of Johnson & Johnson) in the late 2000s and early 2010s. Below is a concise snapshot of the key intellectual‑property milestones that determine when generic versions might enter the market.

Item Details Implications
Original USPTO patents • US 2008/0277772 – “Methods of treating prostate cancer with enzalutamide” (Filed 2006, granted 2008)
• US 2011/0061692 – “Compounds for inhibiting androgen‑receptor activity” (Filed 2008, granted 2012)		 These patents cover the drug’s composition of matter, methods of use, and certain formulations. Their term is 20 years from the earliest filing date (2006) → expires 2026.
Key European patents (EPO, UK, etc.) • WO 2010/015032 – “Enzalutamide and uses” (Filed 2008, granted 2011)
• EP 2011/039579 – “Pharmaceutical compositions containing enzalutamide”		 European term also 20 years from earliest filing → expires 2028.
Patent “cliff” in the U.S. The USPTO’s 20‑year term from filing means the U.S. exclusivity ends in 2026. After that, U.S. generic manufacturers can file for an Abbreviated New Drug Application (ANDA) if they meet the 505(b)(2) or 505(j) pathways.
Patent “cliff” in the EU 20‑year term → expires 2028. Generic entry may be delayed by patent litigation or “ever‑greening” patents that extend protection.
Key “ever‑green” patents • US 2019/0297712 – “Extended‑release enzalutamide formulation” (Filed 2016, granted 2019) – expires 2036.
• US 2016/0193855 – “Enzalutamide in combination with other agents” – expires 2036.		 These do not affect the core drug’s patent but can block generic versions that use those specific delivery methods or combination regimens until they expire.
Market dynamics • U.S.: First generic expected late 2026–early 2027 if no litigation.
• EU: First generic expected 2029–2030, depending on patent clearance.
• Other regions: Patent expiration varies; e.g., Japan’s original patent (JP 2010‑004761) expires 2028.
Potential impact on pricing Once generics enter, prices for enzalutamide can drop by 70–90 %, improving access for patients and reducing insurer out‑of‑pocket costs.
Regulatory filings to watch • FDA’s “Patent Landscape” reports (2022‑2024) list pending generic applications.
• European Commission’s “Pharmaceuticals Market Entry Regulation” updates on patent clearance.

Quick Takeaway

  • U.S.: Core patents expire 2026 → generic entry possible in 2026‑2027.
  • EU: Core patents expire 2028 → generic entry possible in 2028‑2029.
  • Ever‑green patents (e.g., extended‑release formulations) may hold up generic versions for a few more years, typically until the early 2030s.

How to Use This Information

  1. Clinicians & payers: If you’re planning formulary changes, monitor the FDA’s and EMA’s public databases for pending generic filings.
  2. Patients: Inquire with your pharmacist about the expected availability of generic enzalutamide; most insurance plans will cover the generic once it’s approved.
  3. Pharmaceutical companies: If you’re developing a biosimilar or a new formulation, align your IP strategy to avoid overlapping “ever‑green” claims that could delay market entry.

Disclaimer
The above dates are based on publicly available patent filing and grant records and should be verified against the most recent USPTO, EPO, and national patent office databases. This information is for educational purposes only and does not constitute medical or legal advice. If you need precise guidance on drug pricing, insurance coverage, or legal implications, consult a qualified professional.



Other Questions About Enzalutamide :

Enzalutamide patent? Cost of enzalutamide apalutamide darolutamide bicalutamide prostate cancer us? Enzalutamide fda exclusivity date? Enzalutamide fda orange book exclusivity date? Enzalutamide (xtandi) market exclusivity period? Enzalutamide original patent expiration date? Enzalutamide fda approval exclusivity date?